Compare Novartis AG (NVS) vs Snap Inc (SNAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Snap Inc — how do they compare? Novartis AG trades at $154.71 (market cap $298.18B), while Snap Inc trades at $5.5 (market cap $9.05B). The key difference: Novartis AG is far larger — about 32.9× Snap Inc's market cap, and Novartis AG pays a 3.02% dividend while Snap Inc pays none. Which is the better fit depends on your goals.
| NVS | SNAP | |
|---|---|---|
Market Cap | $298.18B | $9.05B |
Sector | Health | Media |
52-Week High | $168.62 | $9.09 |
52-Week Low | $118.55 | $3.93 |
Enterprise Value | $339.50B | $10.61B |
Dividend Yield | 3.02% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $156.33, up 1.37% on the day, with a bullish technical signal and strong support near $156. The company reported Q2 2026 earnings that beat expectations, driven by robust oncology drug sales, and reaffirmed full-year guidance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%, while valuation ratios like P/E of 23.61 and P/B of 7.15 reflect premium pricing. Recent news highlights institutional buying and CEO confidence in the growth pipeline.
The outlook for NVS is positive, supported by earnings momentum and a diversified drug portfolio, but risks include generic competition for Entresto and pricing pressures. Analyst consensus is mixed with 24% buy ratings, indicating cautious optimism. Investment appeal hinges on execution of new drug launches and offsetting legacy product declines.
SNAP trades at $5.33, up 2.3% today, with a bullish technical signal and recent Q2 2026 earnings beating expectations. Revenue grew 19% year-over-year to $1.60 billion, and adjusted EBITDA surged 505%. The stock shows improving operational trends but remains unprofitable, with a net income margin of -4.9% for 2025. Analyst consensus price target is $7.02, suggesting potential upside from current levels.
Outlook hinges on sustained advertising recovery and cost discipline. Risks include persistent losses, high debt, and competitive pressure. Institutional sentiment is mixed, with 38% buy ratings but recent insider selling. The stock offers speculative growth potential if profitability improves, but volatility may persist near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Snap Inc
Snap, which refers to itself as a camera company, has one of the most popular social networking apps, Snapchat, in developed regions such as North America and Europe. The firm has approximately 158 million daily active users. Snap generates nearly all of its revenue from advertising with 88% coming from the U.S. The firm is headquartered in Venice, California.
Read more on SNAP →
